Clinic
Sutter West Bay Hospitals
Sutter West Bay Hospitals was paid $73K by Medicaid between Jan 2018 and Dec 2024, across 253 billing codes. Its largest line is 99283, emergency room visit (moderate) — 14% of everything it billed.
33Billing provider infoSUTTER WEST BAY HOSPITALS
SAN FRANCISCO, CA 94115
SAN FRANCISCO, CA 94115
33aNPI1780742981assigned 12/04/2006
33bProvider typeClinic/Center
28Total paid$73K
24GClaims300,035
24DCodes billed253
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinic/Center providers in California
Rank by total paid#285 of 504
Median peer was paid$102K
This provider vs. median0.7×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 47,014 | $15K | |
| 2019 | 45,107 | $21K | |
| 2020 | 37,537 | $14K | |
| 2021 | 42,309 | $4K | |
| 2022 | 43,229 | $4K | |
| 2023 | 41,930 | $9K | |
| 2024incomplete | 42,909 | $5K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 14% | 448 | 398 | $11K |
| 99201 | 9.7% | 134 | 125 | $7K | |
| 0121 | 7.3% | 1,179 | 1,102 | $5K | |
| 0360 | 7.0% | 696 | 688 | $5K | |
| 0450 | Emergency room services | 6.8% | 10,498 | 9,701 | $5K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 5.7% | 2,050 | 1,966 | $4K |
| 82077 | 5.6% | 483 | 469 | $4K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 5.6% | 2,053 | 1,970 | $4K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 4.1% | 3,036 | 2,935 | $3K |
| 86481 | 2.7% | 314 | 311 | $2K | |
| Z7502 | 2.1% | 41 | 40 | $2K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.8% | 617 | 587 | $1K |
241 more codes
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.8% | 2,053 | $1K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.6% | 3,794 | $1K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.6% | 1,932 | $1K |
| Z9725 | 1.5% | 26 | $1K | |
| 0710 | 1.5% | 605 | $1K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.3% | 2,195 | $951.94 |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 1.1% | 1,092 | $797.30 |
| 88341 | 1.1% | 386 | $773.86 | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,878 | $695.27 |
| 80053 | Comprehensive metabolic panel | <1% | 15,817 | $685.04 |
| T1999 | Miscellaneous therapeutic items and supplies, retail purchases, not otherwise classified; identify product in "remarks" | <1% | 7,591 | $676.92 |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 224 | $641.76 |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 16,644 | $593.64 |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 915 | $517.34 |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,842 | $421.30 |
| J3490 | Unclassified drugs | <1% | 1,080 | $405.16 |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 7,065 | $340.06 |
| 71045 | Radiologic examination, chest; single view | <1% | 1,757 | $329.38 |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 871 | $271.94 |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 665 | $269.18 |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,348 | $262.46 |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 159 | $218.64 |
| 84484 | <1% | 2,657 | $207.88 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 972 | $206.95 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 4,120 | $196.93 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 2,045 | $191.77 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,327 | $188.84 |
| 97750 | <1% | 1,934 | $178.02 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,038 | $159.19 |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,527 | $158.61 |
| Q3014 | Telehealth originating site facility fee | <1% | 2,584 | $150.60 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 6,089 | $150.21 |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 1,360 | $137.20 |
| 0301 | <1% | 4,025 | $126.76 | |
| 0306 | <1% | 2,216 | $125.44 | |
| 76830 | Ultrasound, transvaginal | <1% | 852 | $118.51 |
| J2704 | Injection, propofol, 10 mg | <1% | 1,330 | $118.36 |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 931 | $113.66 |
| 0320 | <1% | 257 | $110.64 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 2,268 | $104.94 |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,910 | $102.56 |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 7,001 | $86.51 |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 208 | $79.39 |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,957 | $79.10 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 3,030 | $76.96 |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 2,483 | $76.65 |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 166 | $74.24 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 634 | $72.91 |
| 0370 | <1% | 976 | $71.72 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,024 | $70.26 |
| 93350 | <1% | 403 | $68.94 | |
| 85610 | <1% | 3,073 | $67.46 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 55 | $66.74 |
| 0949 | <1% | 240 | $63.71 | |
| 73630 | <1% | 139 | $62.32 | |
| 93017 | <1% | 1,107 | $60.25 | |
| 0730 | <1% | 1,279 | $59.67 | |
| 83690 | <1% | 2,138 | $58.77 | |
| 81001 | <1% | 4,238 | $49.80 | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 1,845 | $49.76 |
| 87040 | <1% | 492 | $47.88 | |
| 97165 | <1% | 95 | $45.60 | |
| 81025 | <1% | 1,291 | $45.37 | |
| 87186 | <1% | 144 | $42.97 | |
| 73610 | <1% | 61 | $42.36 | |
| 84702 | <1% | 1,044 | $41.70 | |
| 0250 | <1% | 5,369 | $41.41 | |
| 87400 | <1% | 765 | $39.77 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,702 | $38.64 |
| 86592 | <1% | 996 | $38.23 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 444 | $37.33 |
| 92012 | Ophthalmological services: medical examination and evaluation, intermediate, established patient | <1% | 46 | $37.15 |
| 0310 | <1% | 438 | $35.29 | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 182 | $34.93 |
| 0510 | <1% | 2,002 | $34.10 | |
| 83880 | <1% | 339 | $33.77 | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 5,143 | $32.55 |
| 71250 | <1% | 1,419 | $32.35 | |
| 83735 | <1% | 1,643 | $27.52 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 3,052 | $27.27 |
| 77080 | <1% | 311 | $25.78 | |
| 87340 | <1% | 895 | $25.64 | |
| 82105 | <1% | 1,548 | $24.06 | |
| 85730 | <1% | 1,464 | $23.29 | |
| 81003 | <1% | 2,223 | $22.78 | |
| 82728 | <1% | 1,305 | $22.63 | |
| 86901 | <1% | 1,137 | $21.72 | |
| 86900 | <1% | 1,268 | $21.22 | |
| 80061 | Lipid panel | <1% | 4,466 | $20.67 |
| 87420 | <1% | 363 | $20.00 | |
| 88342 | <1% | 2,054 | $19.91 | |
| 86140 | <1% | 1,124 | $14.36 | |
| 83550 | <1% | 610 | $14.26 | |
| 86850 | <1% | 724 | $12.66 | |
| 83540 | <1% | 851 | $10.74 | |
| 0305 | <1% | 3,446 | $9.94 | |
| 0324 | <1% | 1,169 | $9.71 | |
| 86704 | <1% | 119 | $9.64 | |
| 86803 | <1% | 1,048 | $9.13 | |
| 85652 | <1% | 1,152 | $7.07 | |
| 87081 | <1% | 111 | $4.50 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 64 | $2.09 |
| 0307 | <1% | 1,222 | $2.03 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 3,803 | $0.55 |
| 85027 | <1% | 690 | $0.39 | |
| 77066 | Tomosynthesis, mammo | 0% | 430 | $0.00 |
| 0430 | 0% | 475 | $0.00 | |
| 0302 | 0% | 2,481 | $0.00 | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 0% | 2,759 | $0.00 |
| 84100 | 0% | 42 | $0.00 | |
| 93226 | 0% | 88 | $0.00 | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 0% | 898 | $0.00 |
| 0300 | 0% | 1,541 | $0.00 | |
| 97039 | 0% | 16,673 | $0.00 | |
| 76642 | 0% | 581 | $0.00 | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | 0% | 780 | $0.00 |
| 82570 | 0% | 1,120 | $0.00 | |
| 71271 | 0% | 559 | $0.00 | |
| 80076 | 0% | 477 | $0.00 | |
| 77334 | 0% | 65 | $0.00 | |
| 0122 | 0% | 968 | $0.00 | |
| 78815 | Positron emission tomography (PET) for limited area imaging | 0% | 883 | $0.00 |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 0% | 165 | $0.00 |
| 0111 | 0% | 44 | $0.00 | |
| 93225 | 0% | 88 | $0.00 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 128 | $0.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 13 | $0.00 |
| 59025 | Fetal non-stress test | 0% | 2,464 | $0.00 |
| 0272 | 0% | 1,828 | $0.00 | |
| 82977 | 0% | 213 | $0.00 | |
| 0750 | 0% | 196 | $0.00 | |
| 84439 | 0% | 1,373 | $0.00 | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 0% | 136 | $0.00 |
| 0402 | 0% | 236 | $0.00 | |
| 77336 | 0% | 241 | $0.00 | |
| 74170 | 0% | 39 | $0.00 | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | 0% | 193 | $0.00 |
| 76770 | 0% | 104 | $0.00 | |
| 94729 | 0% | 24 | $0.00 | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 0% | 557 | $0.00 |
| 77065 | Tomosynthesis, mammo | 0% | 54 | $0.00 |
| H1003 | Prenatal care, at-risk enhanced service; education | 0% | 30 | $0.00 |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 0% | 88 | $0.00 |
| 93325 | 0% | 66 | $0.00 | |
| 84156 | 0% | 59 | $0.00 | |
| 0351 | 0% | 52 | $0.00 | |
| 74178 | 0% | 39 | $0.00 | |
| 94726 | 0% | 24 | $0.00 | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 0% | 58 | $0.00 |
| 0460 | 0% | 101 | $0.00 | |
| 99284 | Emergency room visit (serious) | 0% | 62 | $0.00 |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | 0% | 42 | $0.00 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 31 | $0.00 |
| 94060 | 0% | 12 | $0.00 | |
| 59426 | 0% | 47 | $0.00 | |
| 86038 | 0% | 12 | $0.00 | |
| 0762 | 0% | 37 | $0.00 | |
| 72141 | 0% | 28 | $0.00 | |
| 71010 | 0% | 17 | $0.00 | |
| 84550 | 0% | 40 | $0.00 | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 0% | 107 | $0.00 |
| 82947 | 0% | 13 | $0.00 | |
| 87634 | 0% | 14 | $0.00 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 14 | $0.00 |
| 0424 | 0% | 12 | $0.00 | |
| 73030 | 0% | 13 | $0.00 | |
| 0309 | 0% | 32 | $0.00 | |
| 0361 | 0% | 42 | $0.00 | |
| 85045 | 0% | 12 | $0.00 | |
| 84460 | 0% | 13 | $0.00 | |
| 0278 | 0% | 13 | $0.00 | |
| 82043 | 0% | 667 | $0.00 | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 0% | 801 | $0.00 |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | 0% | 2,039 | $0.00 |
| 96040 | 0% | 14 | $0.00 | |
| 85379 | 0% | 24 | $0.00 | |
| 82607 | 0% | 304 | $0.00 | |
| 0258 | 0% | 2,592 | $0.00 | |
| 86706 | 0% | 222 | $0.00 | |
| 76536 | 0% | 630 | $0.00 | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 0% | 1,235 | $0.00 |
| 0171 | Inj, epinephrine (belcher) | 0% | 1,214 | $0.00 |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 0% | 2,249 | $0.00 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 0% | 2,291 | $0.00 |
| 0255 | 0% | 645 | $0.00 | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | 0% | 606 | $0.00 |
| 87486 | 0% | 131 | $0.00 | |
| 0420 | 0% | 748 | $0.00 | |
| 99213 | Doctor's office visit, returning patient (routine) | 0% | 4,441 | $0.00 |
| 0214 | 0% | 250 | $0.00 | |
| 87581 | 0% | 131 | $0.00 | |
| 77063 | Screening digital breast tomosynthesis, bilateral | 0% | 493 | $0.00 |
| 87517 | 0% | 1,055 | $0.00 | |
| 93246 | 0% | 390 | $0.00 | |
| 0409 | 0% | 14 | $0.00 | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | 0% | 265 | $0.00 |
| 0721 | 0% | 724 | $0.00 | |
| 88307 | 0% | 15 | $0.00 | |
| 88142 | 0% | 1,251 | $0.00 | |
| 73560 | 0% | 29 | $0.00 | |
| 87070 | 0% | 135 | $0.00 | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 0% | 851 | $0.00 |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | 0% | 657 | $0.00 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | 0% | 52 | $0.00 |
| 87430 | 0% | 62 | $0.00 | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | 0% | 211 | $0.00 |
| 87077 | 0% | 29 | $0.00 | |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | 0% | 78 | $0.00 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 133 | $0.00 |
| 74183 | 0% | 122 | $0.00 | |
| 97162 | 0% | 17 | $0.00 | |
| 97166 | 0% | 25 | $0.00 | |
| 0352 | 0% | 303 | $0.00 | |
| 92523 | 0% | 508 | $0.00 | |
| 93351 | 0% | 55 | $0.00 | |
| 86762 | 0% | 12 | $0.00 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 42 | $0.00 |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 16 | $0.00 |
| 83605 | 0% | 213 | $0.00 | |
| 82378 | 0% | 26 | $0.00 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 0% | 39 | $0.00 |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | 0% | 33 | $0.00 |
| 93799 | 0% | 12 | $0.00 | |
| 80197 | 0% | 49 | $0.00 | |
| 82784 | 0% | 86 | $0.00 | |
| 99285 | Emergency room visit (most serious) | 0% | 15 | $0.00 |
| 87522 | Neg quan hep c or qual rna | 0% | 12 | $0.00 |
| 88304 | 0% | 12 | $0.00 | |
| 91200 | 0% | 25 | $0.00 | |
| 83615 | 0% | 19 | $0.00 | |
| 83789 | 0% | 14 | $0.00 | |
| 92526 | 0% | 26 | $0.00 | |
| 0270 | 0% | 732 | $0.00 | |
| 82550 | 0% | 13 | $0.00 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 12 | $0.00 |
| 0410 | 0% | 16 | $0.00 | |
| 71020 | 0% | 27 | $0.00 | |
| 0206 | 0% | 16 | $0.00 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 0% | 14 | $0.00 |
| 73502 | 0% | 13 | $0.00 | |
| 84153 | 0% | 27 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHOLDSWORTH, MICHAEL (VICE PRESIDENT OF ADMINISTRATIONS C)
| Provider | Location | Paid |
|---|---|---|
| Sutter West Bay Hospitals | San Francisco, CA | $1.12M |
| Sutter West Bay Hospitals | San Francisco, CA | $3K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.